Black patients who undergo minimally invasive procedures for clogged arteries are more likely to die or be readmitted to the hospital months after the procedure, a Michigan Medicine study finds. Results reveal social determinants of health – including community economic well-being, personal income and wealth, and preexisting health conditions – played a significant role in the outcomes.
Mount Sinai study can help guide proper treatment course for patients depending on heart function and severity of heart damage
Assessment can help stratify high-risk patients for monitoring before, during, and after procedures to improve outcomes
A new study suggests that because of improvements in stent technology and changes in the types of patients receiving stents, the risks of DAPT may now outweigh the benefits for the average patient.
Study outlines better way to identify where stents are necessary
A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.
The Cardiovascular Research Foundation (CRF) has announced that the 2021 Chronic Total Occlusion (CTO) Summit will now take place as a virtual event called CTO Connect. It will take place online February 20-21, 2021.
The conference will feature live case transmissions performed by some of the world’s leading operators along with real-time analysis from world-class faculty members. Live and on-demand sessions will also highlight engaging case-based discussions, challenging cases, and the latest technical developments and refinements in CTO PCI.
The Cardiovascular Research Foundation (CRF) has announced over 30 late-breaking trial and science presentations that will be reported at TCT Connect. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18.
Mount Sinai cardiologist also ranked No. 1 for safety in percutaneous coronary interventions
The Cardiovascular Research Foundation (CRF) is pleased to announce that registration for the annual scientific symposium, TCT Connect, taking place online October 14-18, is free for all attendees and is now open.
The Cardiovascular Research Foundation (CRF) has announced that Transcatheter Cardiovascular Therapeutics (TCT) 2020 will now take place as a virtual event called TCT Connect. The event will take place online October 14-18, 2020 and feature live case-based transmissions from around the globe, late-breaking clinical trials and science, virtual training, and countless opportunities to learn and engage with the brightest minds in interventional cardiovascular medicine.
Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. Their study uses pharmacogenomics and economic analysis of real-world clinical data.
The most common type of heart disease ― coronary artery disease ― affects 6.7% of adults and accounts for 20% of 2 in 10 deaths of adults under age 65. The condition builds over time as inflammation and cholesterol-containing plaques settle in the heart’s arteries, where they can eventually cause narrowing and blockages that lead to a heart attack.
Results from international clinical trial ‘TWILIGHT’ could change standard of care for high-risk cases